Axsome Therapeutics (AXSM) Capital Expenditures (2015 - 2026)

Axsome Therapeutics has reported Capital Expenditures for 12 years, with the latest figure at $121000.0 in Q1 2026.

• Quarterly Capital Expenditures fell 64.2% year-over-year to $121000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $263000.0 (down 48.43% YoY) and the FY2025 annual result came in at $480000.0, up 77.78% from the prior year.
• Capital Expenditures climbed to $121000.0 in Q1 2026 per AXSM's latest filing, from $71000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $371000.0 in Q3 2023 and troughed at $7000.0 in Q4 2023.
• A 5-year average of $126764.7 and a median of $90000.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2022 and 2023: Capital Expenditures surged 40033.04% in 2022, then plunged 96.13% in 2023.
• Over 5 years, Capital Expenditures stood at $181000.0 in 2022, then slumped by 96.13% to $7000.0 in 2023, then soared by 328.57% to $30000.0 in 2024, then soared by 136.67% to $71000.0 in 2025, then jumped by 70.42% to $121000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $121000.0, $71000.0, and $58000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.